|
Paragon 28 inc (NYSE: FNA) |
|
|
|
| |
Paragon 28 inc Outlook |
On November 13 2024 the Paragon 28 inc provided following guidance
Paragon 28 Inc. has recently revised its financial projections for the year 2024, as detailed in their report dated November 13, 2024. This update follows the company's announcement of its third quarter financial results, which reflects a robust performance and an optimistic outlook for the remainder of the year.
In their latest updates, Paragon 28 disclosed its net revenues for the quarter ending September 30, 2024, which totaled $62.3 million. This figure represents a significant year-over-year increase, reflecting an 18.1% rise in reported revenue and a commendable 17.6% increase when adjusted for constant currency fluctuations. Such growth underscores Paragon 28’s strong position within the foot and ankle orthopedic market, emphasizing their commitment to innovation and market leadership.
The company’s enhancement of its net revenue guidance for 2024 is a clear indication of its confidence in continued growth. By revising its estimates upward, Paragon 28 showcases a positive trajectory in its financial performance, suggesting that they are on a path to exceed previous expectations for this fiscal year.
Located in Englewood, Colorado, Paragon 28 (NYSE: FNA) specializes exclusively in medical devices tailored for the foot and ankle orthopedic sector. Their focus and dedication to this niche market position them favorably amidst growing demand for specialized orthopedic solutions, further contributing to their impressive financial results.
Overall, the announcements from Paragon 28 reflect not just a successful third quarter but also set a promising tone for the company's financial outlook going forward into 2024.,
|
On August 9 2024 the Paragon 28 inc provided following guidance
nnParagon 28, Inc. Announces Key Leadership Appointment and Financial Resultsnn
ENGLEWOOD, Colo. — Paragon 28, Inc. (NYSE: FNA), a premier medical device manufacturer dedicated wholly to the foot and ankle orthopedic sector, has made an important announcement regarding its executive team and financial outlook. Effective August 5, 2024, the Company has appointed Chadi Chahine as Chief Financial Officer and Executive Vice-President of Supply Chain Operations.
In conjunction with this leadership change, Paragon 28 also released its financial results for the second quarter of 2024 and provided an update on its revenue expectations. The Company has revised its guidance for net revenue in 2024, though specific updated figures were not disclosed at this time.
Stay tuned for additional insights as we continue to navigate our growth in the orthopedic market and enhance our operational efficiency under the new leadership.,
|
On February 29 2024 the Paragon 28 inc provided following guidance
Paragon 28, Inc. (NYSE: FNA), a prominent medical device company specializing in foot and ankle orthopedics, has released its financial results for the fourth quarter and full year of 2023. The company reported a consolidated net revenue of $60.6 million for the fourth quarter, showing a growth of 17.6% in reported figures and 17.3% in constant currency.
For the full year of 2023, Paragon 28 reported strong financial performance, with robust sales and revenue growth across its product lines. The company's focus on innovation and high-quality products has contributed to its success in the foot and ankle orthopedic market.
Looking ahead to 2024, Paragon 28 provided guidance for its net revenue, expecting to continue its growth trajectory and deliver strong results. The company is committed to meeting the needs of healthcare providers and patients with innovative solutions for foot and ankle care.
Overall, Paragon 28's financial results for 2023 demonstrate its position as a leader in the medical device industry, with a focus on delivering high-quality products and driving growth in the foot and ankle orthopedic market.
|
On January 8 2024 the Paragon 28 inc provided following guidance
the same quarter in the previous year. For the full year ended December 31, 2023, preliminary unaudited net revenue is expected to be in a range of $221.7 to $222 million, reflecting a reported growth of approximately 15% to 15.5% compared to the previous year.
Paragon 28, Inc., a renowned medical device company that specializes in foot and ankle orthopedic products, has released its preliminary unaudited net revenue figures for the fourth quarter and full year ending on December 31, 2023. The company anticipates the net revenue for the fourth quarter of 2023 to fall within the range of $60.3 to $60.6 million. This indicates a commendable growth rate of around 17% to 18% when compared to the same quarter of the previous year.
Furthermore, for the entire year concluding on December 31, 2023, Paragon 28, Inc. estimates its preliminary unaudited net revenue to be in the range of $221.7 to $222 million. This forecast demonstrates a notable growth rate of approximately 15% to 15.5% in comparison to the previous year.
It is worth mentioning that Paragon 28, Inc. has established itself as a leading player in the foot and ankle orthopedic market. The company has consistently developed innovative medical devices to cater to the specific needs of this specialized market segment. The projected growth in net revenue signifies the company's strong performance and its ability to deliver value to its customers.
These preliminary unaudited revenue figures reflect Paragon 28, Inc.'s successful efforts in expanding its market presence and meeting the increasing demand for its products. The company's dedication to providing cutting-edge solutions for foot and ankle orthopedic conditions has evidently paid off, as evidenced by its sustained growth in revenue.
|
|
|
|
